Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Evidence suggests that the justification for a 25 percent import tariff on Canadian goods and services does not hold up to ...

More than 10 million babies have been born through IVF, yet the process is still invasive and costly. Plus, why a venture ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

Kailen Guffey is accused of second-degree murder for allegedly shooting Fattoum, 57, after he refused to turn over a black ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

The FDA elevated Lay's Classic Potato Chips to the highest risk level. Here what to know, and whether the recall impacts Ohio ...

Aaron Siri, a lawyer advising Robert F. Kennedy Jr. as he prepared to become health secretary, petitioned the Food and Drug ...